Next Pharmaceuticals Launches New Natural Product That Boosts Good Cholesterol And Lowers Bad Cholesterol

CARLSBAD, Calif.--(BUSINESS WIRE)--Next Pharmaceuticals today announced the results of a clinical trial on their new-patented heart health ingredient Flavoxine™. The double-blind placebo-controlled clinical trial with 80 subjects showed that Flavoxine™ significantly increased HDL-cholesterol, the so-called “good” cholesterol while significantly reducing LDL-cholesterol, the so-called “bad” cholesterol, and triglycerides. In addition, Flavoxine™ significantly reduced C-reactive protein (CRP), an indicator of inflammation that is now considered to be another positive risk factor for coronary artery disease, and it significantly lowered blood pressure and fasting blood glucose in the overweight individuals with elevated cholesterol levels.